GlassScriptPhysician profile
John Yong Seung Lee
NPI 1972892388
$2,879.92
in general payments reported to CMS, 2019-2025
36 companies · $576 in 2025
The $576 reported for 2025 was more than what 83% of Obstetrics providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $426 · 2020: $109 · 2021: $391 · 2022: $394 · 2023: $400 · 2024: $583 · 2025: $576.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,560.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,559.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $592.81 | 2019-2025 | Veozah, Myrbetriq |
| Abbvie INC. | $440.94 | 2019-2023 | |
| Shield Therapeutics INC | $211.00 | 2023-2025 | Accrufer |
| Sumitomo Pharma America, INC. | $165.94 | 2023-2025 | Myfembree |
| Daiichi Sankyo INC. | $154.82 | 2019-2021 | |
| Pfizer INC. | $141.79 | 2022-2024 | |
| Gilead Sciences, INC. | $100.21 | 2019 | |
| Biogen, INC. | $95.65 | 2024-2025 | Zurzuvae |
| Therapeuticsmd, INC. | $93.15 | 2019-2022 | |
| Exeltis, USA INC. | $70.19 | 2021-2024 | Slynd |
| Evofem Biosciences, INC. | $67.88 | 2021-2024 | Phexxi |
| Mylan Pharmaceuticals INC. | $65.61 | 2020-2021 | |
| Organon LLC | $62.96 | 2021-2025 | Nexplanon |
| Myovant Sciences INC. | $61.22 | 2021-2022 | |
| Intuitive Surgical, INC. | $60.42 | 2024 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Millicent US INC | $55.83 | 2025 | Intrarosa, Femlyv |
| Novo Nordisk INC | $49.07 | 2025 | Wegovy, Ozempic |
| Hologic Sales and Service, LLC | $47.50 | 2023-2024 | Aptima |
| Agile Therapeutics, INC. | $40.13 | 2021-2022 | |
| Baxter Healthcare | $35.89 | 2025 | Seprafilm |
| Scynexis, INC. | $22.88 | 2022 | |
| Roche Diagnostics Corporation | $20.29 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $18.96 | 2024 | Rexulti |
| Mimedx Group, INC. | $18.87 | 2024 | |
| Merck Sharp & Dohme LLC | $18.68 | 2020 | |
| Dexcom, INC. | $18.31 | 2025 | Dexcom G6 Transmitter |
| Aspira Women'S Health INC | $18.15 | 2024 | Ova1 |
| Amgen INC. | $17.95 | 2024 | Evenity |
| Almatica Pharma LLC | $17.04 | 2023 | Loreev Xr |
| Medicem INC. | $15.58 | 2021 | |
| Vertical Pharmaceuticals, LLC | $14.69 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.17 | 2024 | Caplyta |
| Esperion Therapeutics, INC. | $13.82 | 2023 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $13.00 | 2019 | |
| Mayne Pharma Commercial LLC | $12.58 | 2025 | |
| Avion Pharmaceuticals | $11.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.